Cambridge Healthtech Institute’s Inaugural

Bispecific Antibodies for Cancer Immunotherapy

Engineering Next-Generation Biotherapeutics in Immuno-Oncology

August 28-29, 2018

Engaging multiple receptors with bispecific biologics offers the potential to improve upon single-agent checkpoint blockade and promises to be the next generation of immunotherapy. Cambridge Healthtech Institute’s Inaugural Bispecific Antibodies for Cancer Immunotherapy meeting will showcase preclinical, translational and clinical studies on using bispecific antibodies for dual blockade of checkpoint targets, T-cell-redirecting bispecific biologics, overcoming T-cell exhaustion, as well as strategies to improve efficacy and reduce toxicity, and engineer the next generation of bi- and multi-specific biologics.

Cover will include, but is not limited to:

  • Reviving exhausted T-cells with dual costimulation
  • Engaging inhibitory and agonist receptors with bispecific biologics
  • Improving on-target efficacy and limiting off-target immunotoxicity
  • Preclinical and translational research for bispecific antibodies
  • T-cell-redirecting bispecific antibodies
  • Engineering bispecific and multi-specific platforms and constructs

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for priority consideration is February 9, 2018.

All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286